ArticleFrontiers in immunology2025
The PLANES model for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib and PD-1 inhibitors: a multicenter, retrospective study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triple therapy regimen of transcatheter arterial chemoembolization (TACE) plus lenvatinib and PD-1 inhibitors plays a significant role in the treatment of unresectable hepatocellular carcinoma (uHCC). However, only a subset of patients can benefit from it, making it crucial to screen for those who may benefit from the triple therapy regimen. This study constructed and assessed a survival prediction nomogram for uHCC patients undergoing first-line triple therapy. Methods: Using retrospective data from 277 consecutive triple-therapy patients (treated at six Chinese centers between 2018-2023), we constructed the nomogram based on multivariate-derived predictors. Model performance was quantified through discrimination metrics and bootstrapped internal validation. External validation employed an independent cohort (n=208) from three additional institutions. Results: Independent predictors of overall survival (OS) included alpha-fetoprotein (AFP), maximum tumor diameter, tumor number, extrahepatic metastasis, and platelet-to-lymphocyte ratio (PLR). A PLANES model was constructed to predict 12-, 24-, and 36-month OS. The model demonstrated robust discriminative performance, with area under the curve (AUC) values of 0.887, 0.793 and 0.749 for 12-, 24-, and 36-month OS in the training cohort, respectively. External validation yielded AUCs of 0.922, 0.760, and 0.722 for corresponding time points. Conclusions: The PLANES model was successfully established and validated for predict prognosis in unresectable HCC patients receiving first-line triple therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.